CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. (“Cosmos Health” or “Company”) (NASDAQ:)A diversified, integrated, integrated healthcare group engaged in innovative R & D, owner of a pharmaceutical and nutraceutical brand, manufacturer and marketer of health products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, increased his stake in the Company by acquiring 647,809 shares of common stock, valued at $425,000, in all six transactions between December 20, 2024, and January 17, 2025.
As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.
Greg Siokas, CEO of Cosmos Health, said: “I am incredibly excited about our future and remain deeply committed to supporting Cosmos, as I have personally invested more than $17 million since its inception. We are in a period of transformation, and I will continue to support our efforts as we advance our strategy and our vision, advancing our exciting projects.” and expanding our products worldwide.”
Information on the recent transaction of Mr. Siokas:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transaction, including information such as the “Ownership Form”, “ A transaction (JO:) Date”, “Amount”, “Value”, and other relevant information about the shares received by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq: COSM), incorporated in 2009 in Nevada, is a diversified, integrated global healthcare group. The company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life ® , Mediterranation ® , bio-bebe ® , C-Sept ® and C-Scrub ® . Through Cana Laboratories SA, licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures medicines, food additives, cosmetics, biocides, and medical devices in the European Union. Cosmos Health also distributes a wide range of medicines and parapharmaceuticals, including generic and OTC medicines, to wholesale pharmacies and distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D collaborations targeting major health disorders such as obesity, diabetes, and cancer, has advanced in the field of artificial intelligence for drug replacement technology, and is focused on novel R&D of patented nutrients, specialty root extracts, complex generics, and – New OTC. products. Cosmos Health has also entered the telehealth space by acquiring ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is now expanding across Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, and LinkedIn and X.
Forward-Looking Statements
Except for the historical information contained in this news release, the matters described herein may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. , as amended. Statements that precede, follow, or otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or verbs that are future or conditional. such as “will,” “should,” “may,” “could” and “might”, are forward-looking in general and not historical facts, although not all forward-looking statements include the past. These statements, include unknown risks and uncertainties that may have an individual or material impact on the matters discussed, here due to various reasons beyond the Company's control, including, but not limited to, the Company's ability to raise sufficient capital to implement the business plan, the impact of the COVID-19 pandemic and the war of Ukraine, the Company's business, operations and general economy, and the Company's ability to successfully develop and market its proprietary products. and technology. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed in the forward-looking statements contained herein. Readers are urged to read the risk factors disclosed in the Company's filings with the SEC, which are available on the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the first edition of the ACCESS Newswire